Microcap Ledger Artiva Biotherapeutics, Inc. $ARTV
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- Shares outstanding
- 48,890,121 [10-Q 2026-08-06]
What the company doesAI summary of filing
Artiva Biotherapeutics is a clinical-stage biotechnology company developing allogeneic (donor-derived), off-the-shelf natural killer (NK) cell therapies for autoimmune diseases and cancers. The company's lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with monoclonal antibodies in ongoing clinical trials for B-cell driven autoimmune diseases, with refractory rheumatoid arthritis as the lead indication. The company generates no product revenue and is pre-revenue, funding operations through capital raises to advance its clinical programs. Artiva operates a proprietary manufacturing facility in San Diego capable of producing therapeutic doses at estimated commercial costs substantially below competing cell therapies, leveraging manufacturing expertise licensed from strategic partner GC Cell. [10-K 2026-03-10]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$48.52M | −$41.30M | $301.45M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $0.00 | −$83.86M | −$76.75M | $26.70M | [10-K 2026-03-10] |
| FY ended Dec 2024 | $251.0K | −$65.37M | −$55.03M | $40.23M | [10-K 2026-03-10] |
- Quarterly cash burn
- −$20.65M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 24,289,328 | [10-Q 2024-11-12] |
| 2025-03-19 | 24,363,119 | [10-K 2025-03-24] |
| 2025-04-30 | 24,363,119 | [10-Q 2025-05-08] |
| 2025-07-31 | 24,425,762 | [10-Q 2025-08-06] |
| 2025-10-31 | 24,544,904 | [10-Q 2025-11-12] |
| 2026-02-27 | 24,716,672 | [10-K/A 2026-04-30] |
| 2026-04-30 | 24,716,672 | [10-Q 2026-05-08] |
| 2026-07-31 | 48,890,121 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2026-08-06; declared effective 2026-08-14 [S-3 2026-08-06]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-06 | Aslan Fred | sell | 23,463 | $7.20 | [4 2026-10-07] |
| 2026-10-05 | Horan Christopher | sell | 10,340 | $6.84 | [4 2026-10-06] |
| 2026-10-05 | Bush Jennifer | sell | 8,370 | $6.84 | [4 2026-10-06] |
| 2026-10-05 | Banerjee Subhashis | sell | 1,099 | $6.84 | [4 2026-10-06] |
| 2026-10-05 | Aslan Fred | sell | 61,696 | $6.84 | [4 2026-10-06] |
| 2026-09-15 | Aslan Fred | grant | 110,000 | — | [4 2026-09-15] |
| 2026-09-10 | Aslan Fred | grant | 45,000 | — | [4 2026-09-14] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-11 | 8-K | Director or officer change; Shareholder vote results |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | S-3 | Registration statement |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-08-03 | DEF 14A | Proxy statement |
| 2026-07-23 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-07-22 | 8-K | Other events |
| 2026-06-15 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-28 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-19 | 8-K | Director or officer change |
Alerts for $ARTV
Email me when Artiva Biotherapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.